Overview

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Status:
Not yet recruiting

Trial end date:
2025-07-22

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with cetrelimab and cetrelimab alone.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC